Complete remission of advanced lung adenocarcinoma with first-line pembrolizumab monotherapy: Two case reports.
Respir Med Case Rep
; 33: 101469, 2021.
Article
en En
| MEDLINE
| ID: mdl-34401305
ABSTRACT
Immune checkpoint inhibitors (ICIs) are clinically used for treating advanced lung cancer, and some patients have achieved complete remission (CR) with ICI therapy in clinical trials. However, reports summarizing the clinical courses of such patients are limited. We report two cases of lung adenocarcinoma in which CR was achieved with first-line pembrolizumab monotherapy, and the therapeutic effect was maintained after treatment completion. Specific patients can achieve CR, even those who do not meet the previously reported predictors of treatment response other than high programmed death-ligand 1 expression. Thus, biomarkers that can accurately predict the clinical efficacy of ICIs are warranted.
ALK, anaplastic lymphoma kinase; CR, complete remission; CT, computed tomography; Complete remission; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitors; Immunotherapy; Lung adenocarcinoma; NLR, neutrophil-to-lymphocyte ratio; NSCLC, non-small cell lung cancer; OS, overall survival; PD-L1, programmed death-ligand 1; PR, partial response; Pembrolizumab; RR, response rate; TPS, tumor proportion score
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Tipo de estudio:
Prognostic_studies
Idioma:
En
Revista:
Respir Med Case Rep
Año:
2021
Tipo del documento:
Article
País de afiliación:
Japón
Pais de publicación:
ENGLAND
/
ESCOCIA
/
GB
/
GREAT BRITAIN
/
INGLATERRA
/
REINO UNIDO
/
SCOTLAND
/
UK
/
UNITED KINGDOM